{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:13:36Z","timestamp":1778073216892,"version":"3.51.4"},"reference-count":45,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,6]]},"abstract":"<jats:p>Multidrug-resistant tuberculosis (MDR-TB) outcomes are poor partly because of the long treatment duration; the World Health Organization conditionally recommends a shorter course regimen to potentially improve treatment outcomes. Here, we describe the drug susceptibility patterns of a cohort of MDR-TB patients in Haiti and determine the number of likely effective drugs if they were treated with the recommended shorter course regimen. We retrospectively examined drug susceptibility patterns of adults initiating MDR-TB treatment between 2008 and 2015 at the Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections in Port-au-Prince, Haiti. First- and second-line drug susceptibility testing (DST) was analyzed and used to determine the number of presumed effective drugs. Of the 239 patients analyzed, 226 (95%), 183 (77%), 135 (57%), and 38 (16%) isolates were resistant to high-dose isoniazid, ethambutol, pyrazinamide, and ethionamide, respectively. Eight patients (3%) had resistance to either a fluoroquinolone or a second-line injectable and none had extensively resistant TB. Of the 239 patients, 132 (55%) would have fewer than five likely effective drugs in the intensive phase of the recommended shorter course regimen and 121 (51%) would have two or fewer likely effective drugs in the continuation phase. Because of the high rates of resistance to first-line TB medications, about 50% of MDR-TB patients would be left with only two effective drugs in the continuation phase of the recommended shorter course regimen, raising concerns about the effectiveness of this regimen in Haiti and the importance of using DST to guide treatment.<\/jats:p>","DOI":"10.4269\/ajtmh.18-0493","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T07:00:44Z","timestamp":1545894044000},"page":"392-398","source":"Crossref","is-referenced-by-count":5,"title":["Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti"],"prefix":"10.4269","volume":"100","author":[{"given":"Kathleen F.","family":"Walsh","sequence":"first","affiliation":[{"name":"Center for Global Health, Weill Cornell Medicine, New York, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadne","family":"Souroutzidis","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stalz Charles","family":"Vilbrun","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Peeples","sequence":"additional","affiliation":[{"name":"Analysis Group, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Joissaint","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sobieskye","family":"Delva","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamphile","family":"Widmann","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Royal","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Pry","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California;"},{"name":"Centre for Infectious Diseases Research (CIDRZ), Lusaka, Zambia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heejung","family":"Bang","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases Research (CIDRZ), Lusaka, Zambia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean W.","family":"Pape","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi\u2019s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena P.","family":"Koenig","sequence":"additional","affiliation":[{"name":"Division of Global Health Equity, Harvard Medical School, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Global Tuberculosis Report 2017","author":"WHO","year":"2017"},{"key":"b2","series-title":"Eur Respir J","first-page":"1602308","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017"},{"key":"b3","series-title":"Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR\/RR-TB)","author":"WHO","year":"2018"},{"key":"b4","series-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis 2016 Update","author":"WHO","year":"2016"},{"key":"b5","series-title":"Am J Respir Crit Care Med","first-page":"684","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010"},{"key":"b6","series-title":"Int J Tuberc Lung Dis","first-page":"1188","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014"},{"key":"b7","series-title":"Int J Tuberc Lung Dis","first-page":"517","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015"},{"key":"b8","series-title":"Trials","first-page":"353","article-title":"Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial","volume":"15","author":"Nunn","year":"2014"},{"key":"b9","series-title":"STREAM Clinical Trial Results Provide Vital Insight into Nine-Month Treatment Regimen for Multidrug-Resistant Tuberculosis","author":"The UNION","year":"2017"},{"key":"b10","series-title":"Joint Statement on STREAM Stage One MDR-TB Clinical Trial results","author":"Partners in Health","year":"2017"},{"key":"b11","series-title":"Position Statement on the Continued Use of the Shorter MDR-TB Regimen Following an Expedited Review of the STREAM Stage 1 Preliminary Results","author":"WHO","year":"2018"},{"key":"b12","series-title":"Haiti Tuberculosis Profile","author":"WHO","year":"2015"},{"key":"b13","series-title":"Int J Tuberc Lung Dis","first-page":"1140","article-title":"Diagnostic yield of active case finding for tuberculosis and HIV at the household level in slums in Haiti","volume":"21","author":"Rivera","year":"2017"},{"key":"b14","series-title":"Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis Emergency Update 2008","author":"WHO","year":"2008"},{"key":"b15","series-title":"Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis 2011 Update","author":"WHO","year":"2011"},{"key":"b16","series-title":"Am J Trop Med Hyg","first-page":"715","article-title":"Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti","volume":"91","author":"Charles","year":"2014"},{"key":"b17","series-title":"Abstract book, 47th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (the Union)","author":"Vilbrun","year":"2016"},{"key":"b18","series-title":"STREAM Trial (Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for Patients with Multidrug-Resistant Tuberculosis): Preliminary Stage 1 Results","author":"Mukadi","year":"2017"},{"key":"b19","series-title":"Int J Tuberc Lung Dis","first-page":"1","article-title":"Building the evidence base for shortened MDR-TB treatment regimens","volume":"22","author":"Rusen","year":"2018"},{"key":"b20","series-title":"BMC Res Notes","first-page":"809","article-title":"Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam","volume":"8","author":"Hoa","year":"2015"},{"key":"b21","series-title":"PLoS One","first-page":"e7186","article-title":"Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa","volume":"4","author":"Seung","year":"2009"},{"key":"b22","series-title":"Am J Respir Crit Care Med","first-page":"1472","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003"},{"key":"b23","series-title":"BMC Infect Dis","first-page":"593","article-title":"Severe adverse events during second-line tuberculosis treatment in the context of high HIV co-infection in South Africa: a retrospective cohort study","volume":"16","author":"Schnippel","year":"2016"},{"key":"b24","series-title":"PLoS One","first-page":"e94271","article-title":"Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients","volume":"9","author":"Yimer","year":"2014"},{"key":"b25","series-title":"Thorax","first-page":"791","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006"},{"key":"b26","series-title":"Eur Respir J","first-page":"1602308","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"Ahmad Khan","year":"2017"},{"key":"b27","series-title":"Int J Tuberc Lung Dis","first-page":"17","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Trebucq","year":"2018"},{"key":"b28","series-title":"PLoS One","first-page":"e0133869","article-title":"A global perspective on pyrazinamide resistance: systematic review and meta-analysis","volume":"10","author":"Whitfield","year":"2015"},{"key":"b29","series-title":"PLoS One","first-page":"e0187211","article-title":"Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in sub-saharan Africa have concomitant resistance to pyrazinamide","volume":"12","author":"Ngabonziza","year":"2017"},{"key":"b30","series-title":"Clin Infect Dis","first-page":"1364","article-title":"Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis","volume":"59","author":"Bastos","year":"2014"},{"key":"b31","series-title":"J Clin Microbiol","first-page":"300","article-title":"Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"48","author":"Chedore","year":"2010"},{"key":"b32","series-title":"J Clin Microbiol","first-page":"1670","article-title":"Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system","volume":"40","author":"Pfyffer","year":"2002"},{"key":"b33","series-title":"J Microbiol Methods","first-page":"331","article-title":"Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiometric Bactec 460TB system","volume":"55","author":"Kontos","year":"2003"},{"key":"b34","series-title":"Int J Tuberc Lung Dis","first-page":"151","article-title":"Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey","volume":"19","author":"Kamal","year":"2015"},{"key":"b35","series-title":"Int J Tuberc Lung Dis","first-page":"465","article-title":"Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994\u20132001","volume":"8","author":"Vasquez-Campos","year":"2004"},{"key":"b36","series-title":"Int J Tuberc Lung Dis","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"Katiyar","year":"2008"},{"key":"b37","series-title":"PLoS One","first-page":"e0135003","article-title":"High prevalence of inhA promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa","volume":"10","author":"Niehaus","year":"2015"},{"key":"b38","series-title":"Int J Tuberc Lung Dis","first-page":"946","article-title":"Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment","volume":"18","author":"Abate","year":"2014"},{"key":"b39","series-title":"BMC Infect Dis","first-page":"43","article-title":"Extensive transmission of isoniazid resistant M. tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study","volume":"10","author":"Hu","year":"2010"},{"key":"b40","series-title":"Tuberculosis (Edinb)","first-page":"529","article-title":"Molecular mechanism of rifampicin and isoniazid resistance in Mycobacterium tuberculosis from Bangladesh","volume":"92","author":"Rahim","year":"2012"},{"key":"b41","series-title":"BMC Res Notes","first-page":"487","article-title":"Hypertension control and care at Mulago Hospital ambulatory clinic, Kampala-Uganda","volume":"9","author":"Ssinabulya","year":"2016"},{"key":"b42","series-title":"A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects with Drug Resistant Pulmonary Tuberculosis","author":"Global Alliance for TB Drug Development","year":"2015"},{"key":"b43","series-title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients with Multi-Drug Resistant Tuberculosis","author":"Dheda","year":"2015"},{"key":"b44","series-title":"Int J Antimicrob Agents","first-page":"71","article-title":"In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"45","author":"Zhang","year":"2015"},{"key":"b45","series-title":"Sci Rep","first-page":"34293","article-title":"Repurposing clinically approved cephalosporins for tuberculosis therapy","volume":"6","author":"Ramon-Garcia","year":"2016"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/100\/2\/article-p392.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/100\/2\/article-p392.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/100\/2\/article-p392.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T13:43:12Z","timestamp":1722433392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/100\/2\/article-p392.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":45,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.18-0493","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]}}}